<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Registration No. 333-145412</B></P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>POST-EFFECTIVE AMENDMENT NO. 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FORM S-8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>GENEREX BIOTECHNOLOGY CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>(Exact Name of Registrant as Specified in
its Charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>Delaware</b></font></td>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</td>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>98-0178636</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>(State or Other Jurisdiction of</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Incorporation or Organization)</b></P></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>(I.R.S. Employer</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Identification Number)</b></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>555 RICHMOND STREET WEST, SUITE 604</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>TORONTO, ONTARIO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CANADA M5V 3B1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Address of Principal Executive Offices)
(Zip Code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>AMENDED AND RESTATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>GENEREX BIOTECHNOLOGY CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2006 STOCK PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Full Title of the Plan)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Mark
A. Fletcher</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>President
and Chief Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Generex
Biotechnology Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>555
RICHMOND STREET WEST,</B></FONT><B> SUITE 604</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>TORONTO, ONTARIO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CANADA M5V 3B1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(416) 364-2551</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Name, Address and Telephone Number, Including
Area Code, of Agent for Service)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><I>Copies of all communications, including
all communications sent to agent for service, should be sent to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Gary A. Miller</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Eckert Seamans Cherin &amp; Mellott, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Two Liberty Place</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>50 South 16</B></FONT><B><FONT STYLE="font-size: 7pt"><SUP>th</SUP></FONT><FONT STYLE="font-size: 10pt">
Street &ndash; 22</FONT><FONT STYLE="font-size: 7pt"><SUP>nd</SUP></FONT><FONT STYLE="font-size: 10pt"> Floor</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Philadelphia, PA 19102</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(215) 851-8400</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<HR SIZE="3" NOSHADE ALIGN="LEFT" STYLE="width: 100%; color: black">

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: bottom">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Title&nbsp;of&nbsp;Each&nbsp;Class&nbsp;of&nbsp;Securities</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>To&nbsp;Be&nbsp;Registered&nbsp;(1)</b></P></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Amount&nbsp;To&nbsp;Be</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Registered</b></P></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <TD NOWRAP COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Proposed&nbsp;Maximum</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Offering&nbsp;Price</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Per&nbsp;Unit</b></P></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <TD NOWRAP COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Proposed&nbsp;Maximum</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate&nbsp;Offering</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Price</b></P></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td>
    <TD NOWRAP COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Amount&nbsp;Of</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Registration</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Fee</b></P></td>
    <td nowrap style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Common&nbsp;Stock,&nbsp;$.001&nbsp;par&nbsp;value&nbsp;</b></font></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>75,000,000 shares</b></font></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt"><b>0.0244</b></font></td>
    <td nowrap style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>(2)</b></font></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt"><b>&nbsp;$1,830,000</b></font></td>
    <td nowrap style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>(2)</b></font></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt"><b>236</b></font></td>
    <td nowrap style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
</table>

<HR SIZE="3" NOSHADE ALIGN="LEFT" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended,
this post-effective amendment no. 3 to this registration statement covers an indeterminate number of additional shares that may
become issuable under the Amended and Restated Generex Biotechnology Corporation 2006 Stock Plan pursuant to anti-dilution and
adjustment provisions thereof as a result of stock splits, stock dividends or similar transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(2) Estimated solely for the purpose of calculating the registration
fee.&nbsp;&nbsp;Pursuant to Rule 457(c) and (h) under the Securities Act, the proposed maximum offering price per share and the
proposed maximum aggregate offering price have been determined based on the closing price of Generex Biotechnology Corporation&rsquo;s
common stock as reported on the OTC Bulletin Board on June 30, 2014 ($0.0244).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This Post-Effective Amendment No. 3 to Registration Statement File
No. 333-145412 is being filed by the registrant, Generex Biotechnology Corporation (the &ldquo;Company&rdquo;), for the purpose
of increasing the number of shares of common stock to be issued under the Amended and Restated Generex Biotechnology Corporation
2006 Stock Plan (the &ldquo;Plan&rdquo;) by 75,000,000 shares, from 60,000,000 shares to 135,000,000 shares, pursuant to General
Instruction E on Form S-8 (Registration of Additional Securities).&nbsp;&nbsp;The contents of the original registration statement
(File No. 333-145412) are hereby incorporated by reference and made a part hereof.&nbsp;&nbsp;The stockholders of the registrant
approved amending the Plan for this purpose at the annual meeting of stockholders on May 22, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION
STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 3.&nbsp;&nbsp;Incorporation of Documents by Reference.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following documents heretofore filed with the SEC by us under
the Securities and Exchange Act of 1934, as amended, are incorporated herein by reference:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">(a)</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">The Company&rsquo;s Annual Report on Form 10-K filed with the SEC on October 3, 2013 , for the year ended July&nbsp;31, 2013;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">(b)</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">The Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on June 6, 2014 , for the quarter ended April 30, 2014; </font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">(c)</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">The portions of the Company&rsquo;s Definitive Proxy Statement on Schedule 14A that are deemed &ldquo;filed&rdquo; with the SEC under the Securities Exchange Act of 1934, filed on April 1, 2014;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">(d)</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">The Company&rsquo;s Current Reports on Form 8-K filed with the SEC on November 1, 2013, January 10, 2014, January 15, 2014, March 28, 2014 and May 23, 2014; and</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">(e)</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">The description of the Company&rsquo;s common stock contained in the Company&rsquo;s Form 10 filed with the SEC on December 14, 1998, as amended by a Form 10/A filed with the SEC on February 24, 1999, and including any amendment or report subsequently filed for the purpose of updating the description.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">All documents subsequently filed by the Company pursuant to Sections
13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, prior to the filing of a post-effective amendment which indicates
that all securities then offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be
incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents.&nbsp;&nbsp;Any
statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be
modified or superseded for purposes of this registration statement to the extent that such statement is modified or superseded
by a subsequently filed document which also is or is deemed to be incorporated by reference herein.&nbsp;&nbsp;Any such statement
so modified or superseded shall not be deemed to constitute a part of this registration statement except as so modified or superseded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 5.&nbsp;&nbsp;Interests of Named Experts and Counsel.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain members of the firm of Eckert Seamans Cherin &amp; Mellott,
LLC own additional shares (less than one percent in total) that they purchased from time to time for cash, either from us or in
the public market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.&nbsp;&nbsp;Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">Pursuant to Form S-8, Part II, Item 8(b), the Generex
Biotechnology Corporation 2006 Stock Plan is not subject to the requirements of ERISA, and no action will be taken to qualify said
plan under Section 401 of the Internal Revenue Code of 1986, as amended.</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><font style="font-size: 10pt"><b>Exhibit</b></font></td>
    <td colspan="2" style="padding-bottom: 1.5pt">&nbsp;</td>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 12pt"><font style="font-size: 10pt"><b>Description of Exhibit</b></font><b><font style="font-size: 7pt"><sup>(1)</sup></font></b></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">3(i)(a)</font></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3"><font style="font-size: 10pt">Restated Certificate of Incorporation of Generex Biotechnology Corporation (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation&rsquo;s Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 filed on October 26, 2009)</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">3(i)(b)</font></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certificate of Designation of Preferences, Rights and Limitations
        of Series A 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation&rsquo;s
        Current Report on Form 8-K filed on July 11, 2011).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3(i)(c)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certificate of Designation of Preferences, Rights and Limitations
        of Series B 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation&rsquo;s
        Current Report on form 8-K filed on February 1, 2012)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">3(i)(d)</font></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certificate of Designation of Preferences, Rights and Limitations
        of Series C 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation&rsquo;s
        Current Report on Form 8-K filed on August 8, 2012).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3(i)(e)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3"><font style="font-size: 10pt">Certificate of Designation of Preferences, Rights and Limitations of Series D 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation&rsquo;s Current Report on form 8-K filed on December 11, 2012)</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">3(i)(f)</font></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certificate of Amendment to Restated Certificate of Incorporation
        of Generex Biotechnology Corporation (incorporated by reference Appendix E to the Company&rsquo;s Definitive Proxy Statement filed
        with the SEC on January 31, 2013)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">3(i)(g)</font></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certificate of Designation of Preferences, Rights and Limitations
        of Series E 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation&rsquo;s
        Current Report on form 8-K filed on June 17, 2013)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">3(i)(h)</font></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3"><font style="font-size: 10pt">Certificate of Designation of Preferences, Rights and Limitations of Series F 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation&rsquo;s Current Report on form 8-K filed on March 28, 2014)</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<TR>
    <TD STYLE="vertical-align: top">3(ii)</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">Amended and Restated By-Laws of Generex Biotechnology Corporation (incorporated by reference to Exhibit 3.2(ii) to Generex Biotechnology Corporation&rsquo;s Report on Form 8-K filed December 5, 2007)</TD>
    <TD COLSPAN="2" STYLE="font-size: 12pt">&nbsp;</TD></TR>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">4.3</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top; text-indent: -2.55pt"><font style="font-size: 10pt">&nbsp;Amended and Restated Generex Biotechnology Corporation 2006 Stock Plan (incorporated by reference Appendix D to the Company&rsquo;s Definitive Proxy Statement filed with the SEC on April 1, 2014)</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">5.1</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">Opinion of Eckert Seamans Cherin &amp; Mellott, LLC regarding the legality of the securities being registered</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">23.1</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">Consent of MNP LLP</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 12pt">&nbsp;</TD></TR>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">23.2</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">Consent of MSCM LLP</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">23.3</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">Consent of Eckert Seamans Cherin &amp; Mellott, LLC (included in Exhibit 5.1)</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">24.1</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">Power of Attorney (included on signature page)</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td colspan="5" style="vertical-align: top; font-size: 12pt"><font style="font-size: 7pt"><sup>(1) </sup></font><font style="font-size: 10pt">In case of incorporation by reference to documents filed by the Company under the Exchange Act, the Company&rsquo;s file number under the Exchange Act is 000-25169.</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="width: 7px">&nbsp;</td>
    <td style="width: 3px">&nbsp;</td>
    <td style="width: 1px">&nbsp;</td>
    <td style="width: 671px">&nbsp;</td>
    <td style="width: 0px">&nbsp;</td>
    <td style="width: 8px">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Pursuant to the requirements of the Securities
Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
Form S-8 and has duly caused this Post Effective Amendment No. 3 to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Toronto, Ontario, Canada, on this 3rd day of July 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <td colspan="2"><font style="font-size: 10pt"><b>GENEREX BIOTECHNOLOGY CORPORATION</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</td>
    <TD STYLE="width: 43%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">By:</FONT></td>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;&nbsp;&nbsp;&nbsp;Mark A. Fletcher&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">Mark A. Fletcher, President and CEO</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>







<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below hereby constitutes and appoints Mark A. Fletcher and Stephen Fellows, and each of them, his true and lawful attorneys-in-fact
and agents with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities,
to sign any and all amendments (including additional post-effective amendments) and additions to this Post Effective Amendment
No. 3 and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, and hereby grants
to such attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary
to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">Pursuant to the requirements of the Securities
Act of 1933, this Post Effective Amendment No. 3 has been signed below by the following persons in the capacities and on the dates
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="10" STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"><B>Name</B></TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; padding-left: 4.8pt; border-bottom: Black 1pt solid"><B>Capacity in Which Signed</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top; text-indent: 2.4pt; border-bottom: Black 1pt solid"><B>Date</B></TD></TR>
<TR>
    <TD COLSPAN="10" STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; padding-left: 4.8pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-indent: 2.4pt">&nbsp;</TD></TR>
<tr>
    <TD COLSPAN="10" STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Mark A. Fletcher</FONT></TD>
    <td colspan="3" style="vertical-align: top; padding-left: 4.8pt"><font style="font-size: 10pt">President and Chief Executive Officer </font></td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top; text-indent: 2.4pt"><font style="font-size: 10pt">July 3, 2014</font></td></tr>
<tr>
    <TD COLSPAN="10" STYLE="vertical-align: bottom; border-bottom: white 1pt solid"><FONT STYLE="font-size: 10pt">Mark A. Fletcher</FONT></TD>
    <td colspan="3" style="vertical-align: top; padding-left: 4.8pt"><font style="font-size: 10pt">(Principal Executive Officer)</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <td colspan="3" style="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <TD COLSPAN="10" STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Stephen Fellows</FONT></TD>
    <td colspan="3" style="padding-left: 4.8pt"><font style="font-size: 10pt">Chief Financial, Officer &nbsp;</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top; text-indent: 2.4pt"><font style="font-size: 10pt">July 3, 2014</font></td></tr>
<tr>
    <TD COLSPAN="10" STYLE="vertical-align: top; border-bottom: white 1pt solid"><FONT STYLE="font-size: 10pt">Stephen Fellows</FONT></TD>
    <td colspan="3" style="padding-left: 4.8pt"><font style="font-size: 10pt">(Principal Financial and Accounting Officer)</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <td colspan="3" style="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <TD COLSPAN="10" STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Brian T. McGee</FONT></TD>
    <td colspan="3" style="vertical-align: top; padding-left: 4.8pt"><font style="font-size: 10pt">Director</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top; text-indent: 2.4pt"><font style="font-size: 10pt">July 3, 2014</font></td></tr>
<tr>
    <TD COLSPAN="10" STYLE="vertical-align: top; border-bottom: white 1pt solid"><FONT STYLE="font-size: 10pt">Brian T. McGee</FONT></TD>
    <td colspan="3" style="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <td colspan="3" style="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <TD COLSPAN="10" STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ John P. Barratt</FONT></TD>
    <td colspan="3" style="vertical-align: top; padding-left: 4.8pt"><font style="font-size: 10pt">Director</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top; text-indent: 2.4pt"><font style="font-size: 10pt">July 3, 2014</font></td></tr>
<tr>
    <TD COLSPAN="10" STYLE="vertical-align: top; border-bottom: white 1pt solid"><FONT STYLE="font-size: 10pt">John P. Barratt</FONT></TD>
    <td colspan="3" style="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <td colspan="3" style="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <TD COLSPAN="10" STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ James Anderson</FONT></TD>
    <td colspan="3" style="vertical-align: top; padding-left: 4.8pt"><font style="font-size: 10pt">Director</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top; text-indent: 2.4pt"><font style="font-size: 10pt">July 3, 2014</font></td></tr>
<tr>
    <TD COLSPAN="10" STYLE="vertical-align: top; border-bottom: white 1pt solid"><FONT STYLE="font-size: 10pt">James Anderson</FONT></TD>
    <td colspan="3" style="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <td colspan="3" style="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <TD COLSPAN="10" STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Eric von Hofe</FONT></TD>
    <td colspan="3" style="vertical-align: top; padding-left: 4.8pt"><font style="font-size: 10pt">Director</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top; text-indent: 2.4pt"><font style="font-size: 10pt">July 3, 2014</font></td></tr>
<tr>
    <TD COLSPAN="10" STYLE="vertical-align: top; border-bottom: white 1pt solid"><FONT STYLE="font-size: 10pt">Eric von Hofe</FONT></TD>
    <td colspan="3" style="vertical-align: top">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <TD>&nbsp;</td>
    <TD STYLE="width: 12px">&nbsp;</td>
    <TD STYLE="width: 3px">&nbsp;</td>
    <TD STYLE="width: 12px">&nbsp;</td>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="width: 313px">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="width: 9px">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
</table>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>GENEREX BIOTECHNOLOGY CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><font style="font-size: 10pt"><b>Exhibit</b></font></td>
    <td colspan="2" style="padding-bottom: 1.5pt">&nbsp;</td>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 12pt"><font style="font-size: 10pt"><b>Description of Exhibit</b></font><b><font style="font-size: 7pt"><sup>(1)</sup></font></b></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">3(i)(a)</font></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3"><font style="font-size: 10pt">Restated Certificate of Incorporation of Generex Biotechnology Corporation (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation&rsquo;s Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 filed on October 26, 2009)</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">3(i)(b)</font></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certificate of Designation of Preferences, Rights and Limitations
        of Series A 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation&rsquo;s
        Current Report on Form 8-K filed on July 11, 2011).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3(i)(c)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certificate of Designation of Preferences, Rights and Limitations
        of Series B 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation&rsquo;s
        Current Report on form 8-K filed on February 1, 2012)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">3(i)(d)</font></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certificate of Designation of Preferences, Rights and Limitations
        of Series C 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation&rsquo;s
        Current Report on Form 8-K filed on August 8, 2012).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3(i)(e)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3"><font style="font-size: 10pt">Certificate of Designation of Preferences, Rights and Limitations of Series D 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation&rsquo;s Current Report on form 8-K filed on December 11, 2012)</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">3(i)(f)</font></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certificate of Amendment to Restated Certificate of Incorporation
        of Generex Biotechnology Corporation (incorporated by reference Appendix E to the Company&rsquo;s Definitive Proxy Statement filed
        with the SEC on January 31, 2013)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">3(i)(g)</font></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certificate of Designation of Preferences, Rights and Limitations
        of Series E 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation&rsquo;s
        Current Report on form 8-K filed on June 17, 2013)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <td colspan="2"><font style="font-size: 10pt">3(i)(h)</font></td>
    <td colspan="2">&nbsp;</td>
    <td colspan="3"><font style="font-size: 10pt">Certificate of Designation of Preferences, Rights and Limitations of Series F 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation&rsquo;s Current Report on form 8-K filed on March 28, 2014)</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<TR>
    <TD STYLE="vertical-align: top">3(ii)</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">Amended and Restated By-Laws of Generex Biotechnology Corporation (incorporated by reference to Exhibit 3.2(ii) to Generex Biotechnology Corporation&rsquo;s Report on Form 8-K filed December 5, 2007)</TD>
    <TD COLSPAN="2" STYLE="font-size: 12pt">&nbsp;</TD></TR>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">4.3</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top; text-indent: -2.55pt"><font style="font-size: 10pt">&nbsp;Amended and Restated Generex Biotechnology Corporation 2006 Stock Plan (incorporated by reference Appendix D to the Company&rsquo;s Definitive Proxy Statement filed with the SEC on April 1, 2014)</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">5.1</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">Opinion of Eckert Seamans Cherin &amp; Mellott, LLC regarding the legality of the securities being registered</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">23.1</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">Consent of MNP LLP</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 12pt">&nbsp;</TD></TR>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">23.2</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">Consent of MSCM LLP</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">23.3</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">Consent of Eckert Seamans Cherin &amp; Mellott, LLC (included in Exhibit 5.1)</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">24.1</font></td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top"><font style="font-size: 10pt">Power of Attorney (included on signature page)</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td colspan="5" style="vertical-align: top; font-size: 12pt"><font style="font-size: 7pt"><sup>(1) </sup></font><font style="font-size: 10pt">In case of incorporation by reference to documents filed by the Company under the Exchange Act, the Company&rsquo;s file number under the Exchange Act is 000-25169.</font></td>
    <td colspan="2" style="font-size: 12pt">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="width: 7px">&nbsp;</td>
    <td style="width: 3px">&nbsp;</td>
    <td style="width: 1px">&nbsp;</td>
    <td style="width: 671px">&nbsp;</td>
    <td style="width: 0px">&nbsp;</td>
    <td style="width: 8px">&nbsp;</td></tr>
</table>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "gnbt070214forms8.htm", "description": "FORM S-8", "secsgml_size_bytes": 58032}]
{"company-data": {"conformed-name": "GENEREX BIOTECHNOLOGY CORP", "cik": "0001059784", "assigned-sic": "2834", "irs-number": "820490211", "state-of-incorporation": "DE", "fiscal-year-end": "0314"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-197234", "film-number": "14959768"}, "business-address": {"street1": "33 HARBOUR SQ", "street2": "STE 202", "city": "TORONTO ONTARIO CANADA", "state": "A1", "zip": "M5J 2G2", "phone": "4163642551"}, "mail-address": {"street1": "33 HARBOUR SQ", "street2": "STE 202", "city": "TORONTO ONTARIO CA", "state": "A1", "zip": "M5J 2G2"}}
Registration No. 333-145412
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
POST-EFFECTIVE AMENDMENT NO. 3
TO
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
GENEREX BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in
its Charter)
________________
Delaware
98-0178636
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification Number)
555 RICHMOND STREET WEST, SUITE 604
TORONTO, ONTARIO
CANADA M5V 3B1
(Address of Principal Executive Offices)
(Zip Code)
AMENDED AND RESTATED
GENEREX BIOTECHNOLOGY CORPORATION
2006 STOCK PLAN
(Full Title of the Plan)
________________
Mark
A. Fletcher
President
and Chief Executive Officer
Generex
Biotechnology Corporation
555
RICHMOND STREET WEST,
SUITE 604
TORONTO, ONTARIO
CANADA M5V 3B1
(416) 364-2551
(Name, Address and Telephone Number, Including
Area Code, of Agent for Service)
________________
Copies of all communications, including
all communications sent to agent for service, should be sent to:
Gary A. Miller
Eckert Seamans Cherin & Mellott, LLC
Two Liberty Place
50 South 16
th
Street – 22
nd
Floor
Philadelphia, PA 19102
(215) 851-8400
CALCULATION OF REGISTRATION FEE
Title of Each Class of Securities
To Be Registered (1)
Amount To Be
Registered
Proposed Maximum
Offering Price
Per Unit
Proposed Maximum
Aggregate Offering
Price
Amount Of
Registration
Fee
Common Stock, $.001 par value
75,000,000 shares
$
0.0244
(2)
$
$1,830,000
(2)
$
236
(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended,
this post-effective amendment no. 3 to this registration statement covers an indeterminate number of additional shares that may
become issuable under the Amended and Restated Generex Biotechnology Corporation 2006 Stock Plan pursuant to anti-dilution and
adjustment provisions thereof as a result of stock splits, stock dividends or similar transactions.
(2) Estimated solely for the purpose of calculating the registration
fee.  Pursuant to Rule 457(c) and (h) under the Securities Act, the proposed maximum offering price per share and the
proposed maximum aggregate offering price have been determined based on the closing price of Generex Biotechnology Corporation's
common stock as reported on the OTC Bulletin Board on June 30, 2014 ($0.0244).
EXPLANATORY NOTE
This Post-Effective Amendment No. 3 to Registration Statement File
No. 333-145412 is being filed by the registrant, Generex Biotechnology Corporation (the "Company"), for the purpose
of increasing the number of shares of common stock to be issued under the Amended and Restated Generex Biotechnology Corporation
2006 Stock Plan (the "Plan") by 75,000,000 shares, from 60,000,000 shares to 135,000,000 shares, pursuant to General
Instruction E on Form S-8 (Registration of Additional Securities).  The contents of the original registration statement
(File No. 333-145412) are hereby incorporated by reference and made a part hereof.  The stockholders of the registrant
approved amending the Plan for this purpose at the annual meeting of stockholders on May 22, 2014.
PART II
INFORMATION REQUIRED IN THE REGISTRATION
STATEMENT
Item 3.  Incorporation of Documents by Reference.
The following documents heretofore filed with the SEC by us under
the Securities and Exchange Act of 1934, as amended, are incorporated herein by reference:
(a)
The Company's Annual Report on Form 10-K filed with the SEC on October 3, 2013 , for the year ended July 31, 2013;
(b)
The Company's Quarterly Report on Form 10-Q filed with the SEC on June 6, 2014 , for the quarter ended April 30, 2014;
(c)
The portions of the Company's Definitive Proxy Statement on Schedule 14A that are deemed "filed" with the SEC under the Securities Exchange Act of 1934, filed on April 1, 2014;
(d)
The Company's Current Reports on Form 8-K filed with the SEC on November 1, 2013, January 10, 2014, January 15, 2014, March 28, 2014 and May 23, 2014; and
(e)
The description of the Company's common stock contained in the Company's Form 10 filed with the SEC on December 14, 1998, as amended by a Form 10/A filed with the SEC on February 24, 1999, and including any amendment or report subsequently filed for the purpose of updating the description.
All documents subsequently filed by the Company pursuant to Sections
13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, prior to the filing of a post-effective amendment which indicates
that all securities then offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be
incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents.  Any
statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be
modified or superseded for purposes of this registration statement to the extent that such statement is modified or superseded
by a subsequently filed document which also is or is deemed to be incorporated by reference herein.  Any such statement
so modified or superseded shall not be deemed to constitute a part of this registration statement except as so modified or superseded.
Item 5.  Interests of Named Experts and Counsel.
Certain members of the firm of Eckert Seamans Cherin & Mellott,
LLC own additional shares (less than one percent in total) that they purchased from time to time for cash, either from us or in
the public market.
Item 8.  Exhibits.
Pursuant to Form S-8, Part II, Item 8(b), the Generex
Biotechnology Corporation 2006 Stock Plan is not subject to the requirements of ERISA, and no action will be taken to qualify said
plan under Section 401 of the Internal Revenue Code of 1986, as amended.
Exhibit
Description of Exhibit
(1)
3(i)(a)
Restated Certificate of Incorporation of Generex Biotechnology Corporation (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation's Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 filed on October 26, 2009)
3(i)(b)
Certificate of Designation of Preferences, Rights and Limitations
        of Series A 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation's
        Current Report on Form 8-K filed on July 11, 2011).
3(i)(c)
Certificate of Designation of Preferences, Rights and Limitations
        of Series B 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation's
        Current Report on form 8-K filed on February 1, 2012)
3(i)(d)
Certificate of Designation of Preferences, Rights and Limitations
        of Series C 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation's
        Current Report on Form 8-K filed on August 8, 2012).
3(i)(e)
Certificate of Designation of Preferences, Rights and Limitations of Series D 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation's Current Report on form 8-K filed on December 11, 2012)
3(i)(f)
Certificate of Amendment to Restated Certificate of Incorporation
        of Generex Biotechnology Corporation (incorporated by reference Appendix E to the Company's Definitive Proxy Statement filed
        with the SEC on January 31, 2013)
3(i)(g)
Certificate of Designation of Preferences, Rights and Limitations
        of Series E 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation's
        Current Report on form 8-K filed on June 17, 2013)
3(i)(h)
Certificate of Designation of Preferences, Rights and Limitations of Series F 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation's Current Report on form 8-K filed on March 28, 2014)
3(ii)
Amended and Restated By-Laws of Generex Biotechnology Corporation (incorporated by reference to Exhibit 3.2(ii) to Generex Biotechnology Corporation's Report on Form 8-K filed December 5, 2007)
4.3
Amended and Restated Generex Biotechnology Corporation 2006 Stock Plan (incorporated by reference Appendix D to the Company's Definitive Proxy Statement filed with the SEC on April 1, 2014)
5.1
Opinion of Eckert Seamans Cherin & Mellott, LLC regarding the legality of the securities being registered
23.1
Consent of MNP LLP
23.2
Consent of MSCM LLP
23.3
Consent of Eckert Seamans Cherin & Mellott, LLC (included in Exhibit 5.1)
24.1
Power of Attorney (included on signature page)
(1)
In case of incorporation by reference to documents filed by the Company under the Exchange Act, the Company's file number under the Exchange Act is 000-25169.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
Form S-8 and has duly caused this Post Effective Amendment No. 3 to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Toronto, Ontario, Canada, on this 3rd day of July 2014.
GENEREX BIOTECHNOLOGY CORPORATION
By:
/s/    Mark A. Fletcher
Mark A. Fletcher, President and CEO
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below hereby constitutes and appoints Mark A. Fletcher and Stephen Fellows, and each of them, his true and lawful attorneys-in-fact
and agents with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities,
to sign any and all amendments (including additional post-effective amendments) and additions to this Post Effective Amendment
No. 3 and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, and hereby grants
to such attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary
to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities
Act of 1933, this Post Effective Amendment No. 3 has been signed below by the following persons in the capacities and on the dates
indicated.
Name
Capacity in Which Signed
Date
/s/ Mark A. Fletcher
President and Chief Executive Officer
July 3, 2014
Mark A. Fletcher
(Principal Executive Officer)
/s/ Stephen Fellows
Chief Financial, Officer
July 3, 2014
Stephen Fellows
(Principal Financial and Accounting Officer)
/s/ Brian T. McGee
Director
July 3, 2014
Brian T. McGee
/s/ John P. Barratt
Director
July 3, 2014
John P. Barratt
/s/ James Anderson
Director
July 3, 2014
James Anderson
/s/ Eric von Hofe
Director
July 3, 2014
Eric von Hofe
GENEREX BIOTECHNOLOGY CORPORATION
EXHIBIT INDEX
Exhibit
Description of Exhibit
(1)
3(i)(a)
Restated Certificate of Incorporation of Generex Biotechnology Corporation (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation's Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 filed on October 26, 2009)
3(i)(b)
Certificate of Designation of Preferences, Rights and Limitations
        of Series A 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation's
        Current Report on Form 8-K filed on July 11, 2011).
3(i)(c)
Certificate of Designation of Preferences, Rights and Limitations
        of Series B 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation's
        Current Report on form 8-K filed on February 1, 2012)
3(i)(d)
Certificate of Designation of Preferences, Rights and Limitations
        of Series C 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation's
        Current Report on Form 8-K filed on August 8, 2012).
3(i)(e)
Certificate of Designation of Preferences, Rights and Limitations of Series D 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation's Current Report on form 8-K filed on December 11, 2012)
3(i)(f)
Certificate of Amendment to Restated Certificate of Incorporation
        of Generex Biotechnology Corporation (incorporated by reference Appendix E to the Company's Definitive Proxy Statement filed
        with the SEC on January 31, 2013)
3(i)(g)
Certificate of Designation of Preferences, Rights and Limitations
        of Series E 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation's
        Current Report on form 8-K filed on June 17, 2013)
3(i)(h)
Certificate of Designation of Preferences, Rights and Limitations of Series F 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation's Current Report on form 8-K filed on March 28, 2014)
3(ii)
Amended and Restated By-Laws of Generex Biotechnology Corporation (incorporated by reference to Exhibit 3.2(ii) to Generex Biotechnology Corporation's Report on Form 8-K filed December 5, 2007)
4.3
Amended and Restated Generex Biotechnology Corporation 2006 Stock Plan (incorporated by reference Appendix D to the Company's Definitive Proxy Statement filed with the SEC on April 1, 2014)
5.1
Opinion of Eckert Seamans Cherin & Mellott, LLC regarding the legality of the securities being registered
23.1
Consent of MNP LLP
23.2
Consent of MSCM LLP
23.3
Consent of Eckert Seamans Cherin & Mellott, LLC (included in Exhibit 5.1)
24.1
Power of Attorney (included on signature page)
(1)
In case of incorporation by reference to documents filed by the Company under the Exchange Act, the Company's file number under the Exchange Act is 000-25169.